Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 39

1.

[Comparison of UICC and AJCC 8th edition TNM classifications in uropathology].

Compérat E, Varinot J, Eymerit C, Paner GP, Hansel DE, Amin MB, Moroch J.

Ann Pathol. 2019 Jan 30. pii: S0242-6498(18)30189-5. doi: 10.1016/j.annpat.2018.12.005. [Epub ahead of print] French.

PMID:
30711335
2.

Patterns of recurrence and prognosis in locally advanced FIGO stage IB2 to IIB cervical cancer: Retrospective multicentre study from the FRANCOGYN group.

de Foucher T, Bendifallah S, Ouldamer L, Bricou A, Lavoue V, Varinot J, Canlorbe G, Carcopino X, Raimond E, Monnier L, Graesslin O, Touboul C, Collinet P, Neveu ME, Huchon C, Daraï E, Ballester M; Groupe de Recherche Francogyn, France.

Eur J Surg Oncol. 2018 Dec 30. pii: S0748-7983(18)32012-2. doi: 10.1016/j.ejso.2018.11.014. [Epub ahead of print]

PMID:
30685326
3.

[Uterine leiomyoma and fumarate hydratase deficiency].

De Jesus J, Boudy AS, Varinot J, Just PA, Bendifallah S, Ilenko A, Darai É.

Gynecol Obstet Fertil Senol. 2018 Nov 26. pii: S2468-7189(18)30311-8. doi: 10.1016/j.gofs.2018.10.037. [Epub ahead of print] French. No abstract available.

PMID:
30497940
4.

[Prognostic value of PD-1/PD-L1 expression in upper tract urothelial carcinoma].

Campedel L, Seisen T, Cussenot O, Comperat E, Varinot J, Rouprêt M, Cancel-Tassin G.

Prog Urol. 2018 Dec;28(16):900-905. doi: 10.1016/j.purol.2018.08.009. Epub 2018 Sep 13. Review. French.

PMID:
30219646
5.

Comparison of pelvic and para-aortic lymphadenectomy versus para-aortic lymphadenectomy alone for locally advanced FIGO stage IB2 to IIB cervical cancer using a propensity score matching analysis: Results from the FRANCOGYN study group.

Bendifallah S, de Foucher T, Ouldamer L, Bricou A, Lavoue V, Varinot J, Canlorbe G, Carcopino X, Raimond E, Huguet F, Graesslin O, Touboul C, Collinet P, Huchon C, Daraï E, Ballester M; Groupe de Recherche FRANCOGYN.

Eur J Surg Oncol. 2018 Dec;44(12):1921-1928. doi: 10.1016/j.ejso.2018.08.013. Epub 2018 Aug 30.

PMID:
30213717
6.

Letter to the editor: reply to Valeria Barresi "HOXB13 is not expressed in pleomorphic giant cell carcinoma of the bladder".

Varinot J, Compérat E.

Virchows Arch. 2018 Jun 22. doi: 10.1007/s00428-018-2395-0. [Epub ahead of print] No abstract available.

PMID:
29934658
7.

Comparison of cell cycle progression score with two immunohistochemical markers (PTEN and Ki-67) for predicting outcome in prostate cancer after radical prostatectomy.

Léon P, Cancel-Tassin G, Drouin S, Audouin M, Varinot J, Comperat E, Cathelineau X, Rozet F, Vaessens C, Stone S, Reid J, Sangale Z, Korman P, Rouprêt M, Fromond-Hankard G, Cussenot O.

World J Urol. 2018 Sep;36(9):1495-1500. doi: 10.1007/s00345-018-2290-y. Epub 2018 Apr 20.

PMID:
29679140
8.

[The role of biomarkers in the diagnosis, prognosis and therapy of patients with immuno-oncological treatments of genito-urinary carcinomas].

Compérat E, Eymerit C, Moroch J, Varinot J.

Aktuelle Urol. 2018 Apr;49(2):171-177. doi: 10.1055/a-0573-7895. Epub 2018 Mar 27. German.

PMID:
29587322
9.

A practical guide to bladder cancer pathology.

Compérat E, Varinot J, Moroch J, Eymerit-Morin C, Brimo F.

Nat Rev Urol. 2018 Mar;15(3):143-154. doi: 10.1038/nrurol.2018.2. Epub 2018 Jan 31. Review.

PMID:
29384523
10.

Large nested variant of urothelial carcinoma: a clinicopathological study of 36 cases.

Compérat E, McKenney JK, Hartmann A, Hes O, Bertz S, Varinot J, Brimo F.

Histopathology. 2017 Nov;71(5):703-710. doi: 10.1111/his.13280. Epub 2017 Aug 14.

PMID:
28805264
11.

HOXB13 a useful marker in pleomorphic giant cell adenocarcinoma of the prostate: a case report and review of the literature.

Larnaudie L, Compérat E, Conort P, Varinot J.

Virchows Arch. 2017 Jul;471(1):133-136. doi: 10.1007/s00428-017-2134-y. Epub 2017 May 8. Review.

PMID:
28484843
12.

Urothelial carcinoma in first histological diagnosis of patients over 80 years has distinctive histological features: a retrospective single-institution study of 185 patients.

Furudoï A, Varinot J, Phe V, Roupret M, Bitker MO, Compérat E.

Virchows Arch. 2017 May;470(5):561-565. doi: 10.1007/s00428-017-2099-x. Epub 2017 Mar 9.

PMID:
28280928
13.

Classification of Adult Renal Tumors: An Update.

Compérat E, Varinot J.

Semin Ultrasound CT MR. 2017 Feb;38(1):2-9. doi: 10.1053/j.sult.2016.08.004. Epub 2016 Aug 15. Review.

PMID:
28237277
14.

Re: Analysis of Papillary Urothelial Carcinomas of the Bladder with Grade Heterogeneity: Supportive Evidence for an Early Role of CDKN2A Deletions in the FGFR3 Pathway.

Varinot J, Compérat E.

Eur Urol. 2017 Apr;71(4):690. doi: 10.1016/j.eururo.2017.01.023. Epub 2017 Jan 20. No abstract available.

PMID:
28117111
15.

[Update on molecular classifications and new histological classification of bladder cancer].

Varinot J, Furudoï A, Roupret M, Compérat E.

Prog Urol. 2016 Sep - Oct;26(11-12):600-607. doi: 10.1016/j.purol.2016.08.020. Epub 2016 Sep 20. Review. French.

PMID:
27663304
16.

[From new genetic and histological classifications to direct treatment].

Compérat E, Furudoï A, Varinot J, Rioux-Leclerq N.

Ann Pathol. 2016 Aug;36(4):275-8. doi: 10.1016/j.annpat.2016.06.001. Epub 2016 Jul 26. French.

PMID:
27474530
17.

Immunochemical and molecular assessment of urothelial neoplasms and aspects of the 2016 World Health Organization classification.

Compérat E, Varinot J.

Histopathology. 2016 Nov;69(5):717-726. doi: 10.1111/his.13025. Epub 2016 Sep 16. Review.

PMID:
27353436
18.

HOXB13 expression in metastatic prostate cancer.

Varinot J, Comperat E.

Virchows Arch. 2016 Jul;469(1):121. doi: 10.1007/s00428-016-1949-2. Epub 2016 May 16. No abstract available.

PMID:
27184797
19.

HOXB13 protein expression in metastatic lesions is a promising marker for prostate origin.

Varinot J, Furudoï A, Drouin S, Phe V, Penna RR, Roupret M, Bitker MO, Cussenot O, Compérat E.

Virchows Arch. 2016 May;468(5):619-22. doi: 10.1007/s00428-016-1917-x. Epub 2016 Mar 1.

PMID:
26931741
20.

Apparent diffusion coefficient value is a strong predictor of unsuspected aggressiveness of prostate cancer before radical prostatectomy.

Renard Penna R, Cancel-Tassin G, Comperat E, Mozer P, Léon P, Varinot J, Roupret M, Bitker MO, Lucidarme O, Cussenot O.

World J Urol. 2016 Oct;34(10):1389-95. doi: 10.1007/s00345-016-1789-3. Epub 2016 Feb 22.

PMID:
26902878

Supplemental Content

Loading ...
Support Center